PDF Ebook about: Immutol
Immutol
List of ebooks and manuals about Immutol
34 documents available in our comprehensive collection of Immutol resources. Find practical guides, tutorials, and documentation to enhance your knowledge.
Immutep Collaboration (43ykvs1fpsmkmt.pdf)
229 KBEN 4 pages
Immutep Limited enters clinical trial collaboration and supply agreement with Merck KGaA and Pfizer to evaluate combining eftilagimod alpha with avelumab in...
Immutep Report (44zy9kjl9f3cq9.pdf)
1.4 MBEN 86 pages
Immutep Limited reported a loss of $29,902,624 for the year ended 30 June 2021, up from a loss of $13,468,232 in the previous year, primarily due to a decrease...
Immutep Share Plan (44xpr14c4bb7zf.pdf)
1.06 MBEN 15 pages
Immutep Limited announced a $60 million two-tranche placement of new shares at A$0.52 per share, with the second tranche conditional on shareholder approval at...
Immutep Conference Updates (442zg5c74xyypl.pdf)
220 KBEN 2 pages
Immutep Limited will present updated clinical data from its Phase I TACTI-mel trial and new data on its pre-clinical product candidate IMP761 at industry...
Securities Issuance and Quotation Procedures for Immutep Limited (441fj1n6gcjm6g.pdf)
576 KBEN 14 pages
Document en en
Total Solutions for Immuno-Oncology Research Workflows (Immuno-oncology-total-Solutions-Brochure.pdf)
4.05 MBEN 15 pages
BD offers comprehensive immuno-oncology solutions, from blood and tissue collection to cell staining, enabling deep and robust data.
Immutep Limited Business Update Webcast Slides (443rqqtljzlsz0.pdf)
801 KBEN 13 pages
Immutep Limited presented an update on its business during a webcast on March 26, 2019, at 7:45 AM AEDT/3:45 PM EDT on March 25. The slides, available online, offer insights into the company's activities and should be read in conjunction with official announcements for...
Immutep Limited Updates on LAG-3 Therapeutics (44x450cgnl5yyf.pdf)
2.26 MBEN 33 pages
IMMP), global leader in LAG-3 therapeutics, invites you to its Virtual Healthcare Conference from June 1-4, 2021. The presentation offers a business update and should be read in conjunction with official announcements for comprehensive information.
Immutep Limited: Lapse of Unlisted Options and Remaining Securities Update (44ldnwnjdzk9pb.pdf)
226 KBEN 1 page
Immutep Limited advises that 37,144,524 unlisted options over fully paid ordinary shares have lapsed.
Total remaining securities under ASX Code IMMAL are 79,311 + 102,628 + 847,600 options.
Immutep is a biotechnology company developing LAG-3 related immunotherapeutic products.
Download PDF: The Value of Novel Immuno-Oncology Treatments (AJMC_12_2018_Romley20final.pdf)
2.33 MBEN 12 pages
The human immune system has been hypothesized to play a role in oncogenesis for over 150 years, and immuno-oncology (I-O) therapy has begun to show promise.
Immutep Limited: 1-for-11.8 Entitlement Offer Details and Instructions (446h4lh9q2ds5n.pdf)
2.21 MBEN 56 pages
Immutep Limited is making a 1-for-11.8 non-renounceable entitlement offer of new shares at $0.021 per share, closing on July 30, 2019.
Entitlement Offer Results (4474fk69yfbv3w.pdf)
210 KBEN 2 pages
Immutep Limited announced the results of its fully underwritten entitlement offer, raising $2,721,190.48 from eligible shareholders, with underwriter Bell...
ASX Announcement Form (445kwly0mtzclm.pdf)
540 KBEN 14 pages
Immutep Limited issued 5,000,000 fully paid ordinary shares on 3 June 2019, as a result of the vesting and exercise of performance rights under the Executive...
Director's Interest Notice (44g3kkgnsp3x0h.pdf)
184 KBEN 2 pages
IMMUTEP LIMITED (ASX:IMM) director Mr Grant Chamberlain's relevant interests in securities have changed: he indirectly acquired 360,623 Fully Paid Ordinary...
Consolidation Notice (44b59dnr72hmqv.pdf)
36 KBEN 4 pages
IMMUTEP LIMITED is undergoing a security consolidation with an effective date of Tuesday, November 5, 2019, and a record date of Wednesday, November 6, 2019.
Appendix 3Y: Director's Interest Change - Grant Chamberlain, IMMUTEP LIMITED (43yx7qbxlxzzc8.pdf)
169 KBEN 3 pages
Document en en
R&D Tax Incentive (44j6mc75q4f076.pdf)
252 KBEN 2 pages
Immutep Limited has received a €2,173,454 (~A$3,630,000) research and development tax incentive payment from the French Government under its Crédit d’Impôt...
Form 20-F Report (44n1s4fd7lyrth.pdf)
767 KBEN 137 pages
Immutep Limited filed an annual report with the US Securities and Exchange Commission, submitting Form 20-F for the fiscal year ended June 30, 2020.
Notice of Change of Interests (44wkydt479cjny.pdf)
1.86 MBEN 6 pages
The Bank of New York Mellon Corporation (BNYMC) and its related entities notified Immutep Limited of a change in their substantial holding interest, decreasing...
IMM CEO Update (440brz2fdgrbmk.pdf)
978 KBEN 23 pages
Immutep Limited, a global leader in developing LAG-3 therapeutics, reports strong operational and financial progress, with a focus on LAG-3 immunotherapy,...
Immutep Limited 2021 Annual General Meeting Dates and Virtual Access Details (451kszz7wy4pqh.pdf)
258 KBEN 2 pages
Immutep Limited invites shareholders to its virtual 2021 Annual General Meeting on November 26, 2021, at 10:00 am AEDT. Director nominations for non-board candidates must be received by October 19, 2021. The meeting will be held online due to COVID-19 considerations.
Immutep Limited: LAG-3 Therapeutics Update - EGM Presentation (26 July 2021) (44ymxbh7d6x18b.pdf)
1.43 MBEN 24 pages
IMMP), global leader in LAG-3 therapeutics, presents an update at its Extraordinary General Meeting on 26 July 2021, highlighting business progress and future prospects. Information is for reference only, subject to further clarification, and should be accompanied by past/future...
PDF (44h8cht8ztyqfc.pdf)
266 KBEN 2 pages
Immutep Limited's securities are in a trading halt on the ASX until 29 April 2020 or the release of an announcement at the request of the company. This follows a request under ASX Listing Rule 17.1.
Immutep's TACTI-mel Study Shows Promise: High ORR in Unresectable Melanoma (43vdfj6wxy44z4.pdf)
163 KBEN 2 pages
Immutep Limited reports positive new data from its TACTI-mel Phase I clinical trial, showing an overall response rate of 61% in unresectable or metastatic melanoma patients.
Dutch (56878_EM_04_DUT_KAMA_ERVI_FLDE_LZI.PI_.BCI_.OUS_.KET_.Rev_.3.12152022.pdf)
372 KBNL 5 pages
Het LZI Ketamine-enzym-immuno-assay is een in-vitrodiagnostisch middel voor de kwalitatieve en semi-kwalitatieve bepaling van norketamine in menselijke urine.
Horseshoe Crab Crisis (new-delhi-hscs-erdg.pdf)
124 KBEN 2 pages
The horseshoe crab, a "living fossil", is endangered due to its high medicinal value.
It has a unique shell resembling a horse's hoof and is used in pharmaceutical and clinical industries.
Its immuno-defensive mechanisms are also studied in space research.
Immutep Limited Annual Report Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934 for the Fiscal Year Ended June 30, 2019 (448skvbrqj3qk3.pdf)
943 KBEN 199 pages
The United States Securities and Exchange Commission (SEC) document is an annual report (Form 20-F) for Immutep Limited, an Australian company headquartered in Sydney. It covers the fiscal year ended June 30, 2019, and provides updates on the company's activities and financial...
Student Performance in Medical Laboratory Science: Exam Results (7-B.MLT_Result.pdf)
163 KBEN 1 page
This document outlines exam results for a 7th-semester B.MLT student in 2019, covering subjects like Immuno-Hematology, Blood Bank, Autopsy, Medical Jurisprudence, Biochemistry (Toxicology), Microbiology (Clinical), and various laboratory practicals. It lists student roll...
Neurology Schedule (Module_III_Schedule_8_7_19.pdf)
22 KBEN 1 page
Neuroinflammation, case studies, gut-brain connection, metabolic approaches to Parkinson's and multiple sclerosis.
Download as PDF (2023-03-30_GT_Biopharma_Reports_Fourth_Quarter_and_Full_Year__270.pdf)
80 KBEN 8 pages
GT Biopharma reported its Q4 and full-year 2022 financial results, with a proforma cash position of approximately $23.0 million, including $16.5 million in...
IL1110750 CCR 2016 (ANNUAL_QUALITY_DRINKING_REPORT_2017.pdf)
39 KBEN 6 pages
The sources of drinking water include rivers, lakes, streams, ponds, reservoirs, springs, and wells, which can contain naturally-occurring minerals,...
Purpura thrombopénique immunologique (2015) (www.orpha.netdatapathoProfrUrgences_Purpurathrombopeniqueimmunologique-frPro3002.pdf.pdf)
614 KBFR 15 pages
Le purpura thrombopénique immunologique (PTI) est une maladie auto-immune rare qui peut toucher l’enfant ou l’adulte, caractérisée par une destruction accrue...
Understanding Listeria: Causes, Symptoms, Transmission, and Prevention (ListeriaFINALbrochure.pdf)
1.41 MBEN 1 page
Listeria is a serious foodborne infection caused by the bacterium *Listeria monocytogenes*, found in soil, water, and contaminated foods like uncooked meats and raw milk. It can be carried asymptomatically by animals, leading to contamination of meat and dairy products; pregnant...
S&P/ASX Indices Rebalance March 2021 (44tm5n0xpsn800.pdf)
154 KBEN 9 pages
S&P Dow Jones Indices announced changes to the S&P/ASX Indices effective March 22, 2021, with no changes to the S&P/ASX 20, 50, or 100 Indexes. The S&P/ASX 200 Index saw additions of Codan Limited, Champion Iron Limited, HUB24 Limited, Nickel Mines Limited, Nuix Limited, and...
Popular Keywords
Access our collection of Immutol eBooks for free and learn more about Immutol. These books contain exercises and tutorials to improve your practical skills, at all levels!
To find more books about Immutol, you can use related keywords: Does Immutol Work, Dr Raa Immutol, Immutol, Immutol Complaints, Immutol Norwegian Beta Glucan, Immutol Research Study Results, Immutol Reviews, Immutol Side Effects
You can download PDF versions of the user's guide, manuals and ebooks about Immutol, you can also find and download for free A free online manual (notices) with beginner and intermediate resources.